Abbott to lay off 700 as Xience co-promote winds down

Share this article:
Abbott Laboratories notified 700 employees Wednesday that they will be out of work.

Around 300 of them worked on the company's vascular business, where a six-year-old stent co-promotion deal with Boston Scientific is winding down. Another 200 worked in the company's diagnostics division.

Under the stent deal, a legacy of the two companies' 2005 Guidant acquisition, Abbott manufactured and co-marketed its Xience stent and Boston Scientific's identical Promus stent. Boston Scientific will now take over manufacturing of its follow-on Promus Element stent.

The layoffs were announced the same day Abbott Laboratories announced that fourth quarter earnings jumped 12.3 percent, to $1.6 billion, compared with $1.4 billion for the same period in 2010.

This latest round of cuts is not entirely unexpected. Spokesperson Adelle Infante says that the 200 jobs eliminated in Illinois are part of an efficiency program that was announced four years ago. Infante says California will lose 300 jobs and Puerto Rico 100, with the remainder to be spread across Abbott locations.

Abbott Labs announced a year ago that it would cut 1,900 jobs globally due to economic weakness and health reform, among other causes. This was preceded by their 2010 announcement that they would slash 3,000 jobs by 2012.

The company's top-earning drug, Humira, which is used to treat rheumatoid arthritis, psoriasis and Crohn's disease, had $3.4 billion in domestic fourth-quarter sales and $4.5 billion in international sales.

Deutsche Bank research analyst Barbara Ryan writes in a January research note that Abbott's pipeline is sluggish and that its $7.9 billion in sales for 2011 is not enough to insulate the company, which she predicts will see its next strong seller “later in the decade.”  Ryan also writes that competitors and expiring patents are eating away at the company's generics business as Tricor/Triplix go off patent in 2012 and 2014, Niaspan loses its protection in 2013, Androgel in 2015, and Kaletra in 2016.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...